21986 Investors following Glenmark. Share this News with them.
0
Like this story, share it with millions of investors on M3
Buy Glenmark Pharma, tgt Rs 716: Religare
Religare has maintained buy rating on Glenmark Pharma with target price of Rs 716. Valuation Strong earnings growth expected as the generic business gains scale
Religare has maintained buy rating on Glenmark Pharma with target price of Rs 716, in its June 16, 2008 report. "A leading Indian company to focus on and unlock value from NCE research. Maturing R&D pipeline of eight NCEs and five NBEs, which we have valued at Rs 220/share. Enjoys a wide geographical spread in conjunction with a strong product pipeline for the US and RoW markets. Employing the inorganic route to gain scale in Europe. We have valued the generic business at Rs 496/share. Valuation Strong earnings growth expected as the generic business gains scale. Will continue to benefit from progressive monetising of its R&D pipeline. We have an SOTP-based target price of Rs 716 for the stock" says Religare report.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
|
Budget: 2008, 2009, 2010, 2011, 2012 |
Intuit Money Manager |
RBI Credit Policy | Union Budget | Budget 2012
| Economic Survey
| Railway Budget
| Financial Glossary
|
Message Board |
Moneybhai |
Connect.in.com |
Business Yellow Pages |
India's Premiere Technology Guide | History India
| Up Polls | Latest News
| Mahindra Satyam | Tata Steel | Uninor | Chennai | MMTC | Vodafone Essar | Mutual fund | BSE Sensex | MCX | National missile defense 
